"The release of the positive results of the phase III clinical study of Ameile® is a major breakthrough in the field of targeted therapy for lung cancer in China, signifying that the independent R&D capability of Chinese pharmaceutical companies has reached a world-class level, and is an important milestone in promoting China's innovative drug R&D to go global." Academician Wang Guangji of China Pharmaceutical University remarked at the press conference of the phase III clinical study of Ameile® recently.
Phase III clinical study for first-line treatment achieved positive results
In February 2021, the press conference of the phase III clinical study of Ameile®, themed on "Create Excellence in China and Usher in Meile Era", was held in Shanghai. The conference announced that the phase III study of the third-generation EGFR-TKI Ameile® for first-line treatment of EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) achieved positive results, reaching the preset main study endpoint. The specific study data will be released at subsequent academic conference.
The leading principal investigator of this study, Professor Lu Shun, Chairman of the Society of Lung Cancer of China Anti-Cancer Association and Director of the Department of Oncology of the Chest Hospital Affiliated to Shanghai Jiaotong University, noted that this phase III clinical study of Ameile® is the world's first phase III, randomized, controlled study for Chinese patients in a real sense, with a higher level of evidence and greater applicability to Chinese patients, and the data are even more worthy of anticipation. The release of the results will help to provide more options for first-line treatment of lung cancer patients in China.
Actively expand research on new indications and combination therapy to explore the "maximum accessibility" of lung cancer treatment
To benefit patients is the value of Hansoh Pharma's innovative exploration. According to Professor Lu Shun, the exploration of Ameile® is still ongoing in the fields of targeted combined chemotherapy, targeted antivascular therapy, etc., with infinite potential and possibilities. Since its launch, Ameile® has made in-depth exploration in the field of lung cancer, and a number of registered clinical studies are in progress. It is expected that the results of these studies will provide a more accurate basis for "individualized" treatment of lung cancer patients.
Recommended by guidelines and covered by medical insurance, Ameile® is going global and riding the wave
In May 2020, China CSCO Guidelines for NSCLC 2020 recommended Ameile® for the treatment of advanced NSCLC, fully demonstrating the high recognition of Ameile®'s clinical efficacy and safety by medical experts in China. Through negotiations organized by the National Healthcare Security Administration, Ameile® has successfully entered the National Reimbursement Drug List by virtue of its pharmacoeconomic value. In March 2021, the new version of the National Reimbursement Drug List officially came into effect. As a result, Ameile® will further reduce the financial burden of patients' medication, effectively help patients with long-term standardized treatment, and become an affordable and high-quality drug for lung cancer patients in China.
In July 2020, Hansoh Pharma signed an overseas cooperation agreement with EQRx to jointly conduct global development and research, so as to further expand the therapeutic potential of almonertinib, which is expected to benefit patients worldwide.
Only innovators can go steady and far. Technological innovation is always the distinct gene of Hansoh Pharma, and also the internal driving force and core competitiveness behind its sustainable and steady development. With the mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will, in the future, continue to accelerate the pace of technological innovation, integrate superior resources, innovate, transform and upgrade, speed up the successful launch of more innovative drugs and the introduction of more indications, and contribute its wisdom and strength to further meet the growing health service needs of Chinese people!